Current Report Filing (8-k)
February 02 2023 - 7:39AM
Edgar (US Regulatory)
0001779372
false
0001779372
2023-02-02
2023-02-02
0001779372
us-gaap:CommonStockMember
2023-02-02
2023-02-02
0001779372
us-gaap:WarrantMember
2023-02-02
2023-02-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 2, 2023
HEARTBEAM,
INC.
(Exact
name of Registrant as specified in its charter)
Delaware |
|
001-41060 |
|
47-4881450 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
2118
Walsh Avenue, Suite 210
Santa
Clara, CA 95050
(Address
of principal executive offices, including zip code)
(408)
899-4443
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
BEAT |
|
NASDAQ |
Warrant |
|
BEATW |
|
NASDAQ |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
On
February 1, 2023, HeartBeam, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with
A.G.P./Alliance Global Partners, as sales agent (“A.G.P.”), pursuant to which the Company may offer and sell (the “Offering”),
from time to time, at its option, through or to A.G.P., up to an aggregate of approximately $13,000,000 of shares of the Company’s
common stock, $0.0001 par value per share (the “Shares”). Any Shares to be offered and sold under the Sales Agreement will
be issued and sold pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-269520), filed with the Securities and Exchange Commission (the “SEC”) on February 1, 2023 (the “Registration Statement”)
and the prospectus supplement included therein, relating to the Offering, by methods deemed to be an “at the market offering”
as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or if specified by the Company, by any other method
permitted by law.
Subject
to the terms of the Sales Agreement, A.G.P. will use its commercially reasonable efforts consistent with its normal trading and sales
practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Capital Market to sell the Shares
from time to time, based upon the Company’s instructions (including any price, time or size limits or other customary parameters
or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Shares pursuant to the Sales
Agreement. The Company will pay A.G.P. a commission at a fixed rate of 3.0% of the aggregate gross proceeds from each sale of the Shares
under the Sales Agreement. The Company will also reimburse A.G.P. for certain expenses incurred in connection with the Sales Agreement
and has agreed to provide A.G.P. with customary indemnification rights with respect to certain liabilities, including liabilities under
the Securities Act and the Securities Exchange Act of 1934, as amended.
The
Company currently intends to use any net proceeds from the Offering for working capital and other general corporate purposes, and any
other purposes that may be stated in any future prospectus supplement.
The
foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full
text of the Sales Agreement, which is attached as an exhibit to the Registration Statement and incorporated by reference into this Item
1.01.
This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be
any offer, solicitation or sale of the Shares in any state or country in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or country.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
|
HeartBeam, Inc. |
|
|
|
Date: February 2, 2023 |
By: |
/s/ Richard Brounstein |
|
Name: |
Richard Brounstein |
|
Title: |
Chief Financial Officer |
2
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024